Once neck and neck with Valneva to get the first chikungunya vaccine to market, it now looks like Merck & Co. has admitted defeat as its French rival reaches the finish line. Merck’s contender was ...
After striking out in an attempt to create a niche for its COVID-19 vaccine, Valneva is taking its swings at what it does best—developing, manufacturing and commercializing vaccines for a variety of ...
As safety flags hang over Valneva’s chikungunya vaccine in the U.S. and beyond, French authorities are clamping down on the shot’s use in older adults. France’s public health agency, the Haute ...
LONDON, Aug 8 (Reuters) - With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva (VLS.PA), opens new tab is betting big on a vaccine as it looks beyond disappointing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results